Chiara Mercinelli, GU Medical Oncologist at IRCCS San Raffaele Hospital, shared on X:
“My mentor Andrea Necchi delivered a brilliant presentation today at ASCO 2025!
44% cCR in MIBC with Sacituzumab Govitecan and Pembrolizumab combination in SURE2 trial led to promising biomarker results that could guide future therapeutic choices.
So proud to be part of this wonderful team at San Raffaele Hospital!”
